Demographic and clinical characteristics of the study participants at baseline ITT population
| Placebo + lifestyle | Orlistat + lifestyle | |
|---|---|---|
| n | 1,637 | 1,640 |
| Sex (n [%]) | ||
| Female | 905 (55.3) | 905 (55.2) |
| Male | 732 (44.7) | 735 (44.8) |
| Age (years) | 43.7 ± 8.0 | 43.0 ± 8.0 |
| Weight (kg) | 110.6 ± 16.5 | 110.4 ± 16.3 |
| BMI (kg/m2) | 37.4 ± 4.5 | 37.3 ± 4.2 |
| Waist circumference (cm) | 115.4 ± 10.4 | 115.0 ± 10.4 |
| IGT patients (n [%]) | 344 (21) | 350 (21.3) |
| Whole blood glucose | ||
| Fasting (mmol/l) | 4.6 ± 0.6 | 4.6 ± 0.6 |
| 2 h (mmol/l) | 5.5 ± 1.6 | 5.5 ± 1.6 |
| AUC (mmol · min−1 · l−1) | 799 ± 179 | 804 ± 175 |
| Serum insulin | ||
| Fasting (pmol/l) | 83.6 ± 47.2 | 86.1 ± 50.1 |
| 2 h (pmol/l) | 344.9 ± 298.5 | 370.9 ± 336.7 |
| AUC (nmol · min−1 · l−1) | 47.7 ± 28.4 | 49.7 ± 31.3 |
| Diastolic BP (mmHg) | 82.3 ± 10.0 | 82.0 ± 10.0 |
| Systolic BP (mmHg) | 130.4 ± 15.4 | 130.8 ± 15.8 |
| Total cholesterol (mmol/l) | 5.8 ± 1.0 | 5.8 ± 1.0 |
| LDL cholesterol (mmol/l) | 3.8 ± 0.9 | 3.7 ± 0.9 |
| HDL cholesterol (mmol/l) | 1.2 ± 0.3 | 1.2 ± 0.3 |
| LDL-to-HDL ratio | 3.3 ± 1.0 | 3.2 ± 1.1 |
| Triglycerides (mmol/l) | 1.9 ± 1.2 | 1.9 ± 1.0 |
| Fibrinogen (μmol/l) | 11.7 ± 2.0 | 11.7 ± 2.2 |
| Plasminogen activator inhibitor-1 (U/ml) | 22.9 ± 10.0 | 23.1 ± 10.0 |
| Energy intake (kcal/day) | 2,927 ± 1,148 | 2,909 ± 1,030 |
Data are means ± SD, unless otherwise noted. AUC, area under the curve, BP, blood pressure.